Growth hormone trial for CF wasting halted early

NCT ID NCT00803179

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small Phase 1 trial tested growth hormone in 5 adults with cystic fibrosis who were underweight. The goal was to see if the hormone could help them gain weight and muscle, improve their quality of life, and monitor effects on lung function and diabetes. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Growth hormone (somatropin)

What this could lead to

If it works, this could point toward a treatment to help people with cystic fibrosis gain weight and improve their quality of life.

What could go wrong

This is a very early, tiny trial (only 5 participants) that was terminated, so results are limited. Growth hormone may also affect blood sugar and diabetes risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Umms/Ummhc

    Worcester, Massachusetts, 01655, United States